04 October 2017
Switzerland
Reporter: Jenna Lomax

MPP signs HIV drug deal with Gilead


The UN-backed Medicines Patent Pool (MPP) has signed a new generic manufacturing licence with Gilead Sciences for HIV treatments in Europe and the US.

The licence allows manufacturers to develop and sell generic medicines containing bictegravir, if it is approved in the United States.

Gilead Sciences and the MPP are also expanding the geographical scope of licences on other HIV products, enabling generic medicines to be supplied to additional countries such as Belarus, the Philippines, Malaysia and Ukraine.

The new licences are aimed at providing low- and middle-income countries “improved, simplified treatment options, crucial for people living in resource-limited settings," said Greg Perry, executive director of the MPP.

Lelio Marmora, executive director of Unitaid, MPP's funder, said: “We're tremendously pleased with the MPP and Gilead's collaborative efforts over the many years to improve health outcomes in low- and middle-income countries.”

"Through their joint HIV licensing programme, millions stand to benefit from quality-assured generics of new optimised treatment regimens."

Gregg Alton, executive vice president for corporate and medical affairs at Gilead Sciences, added: “These agreements allow for our licensees to provide generic versions of our latest therapies to people living with HIV in the developing world.”

He added: “Today, more than 10 million people in resource-limited countries are on Gilead-based HIV therapies, which would not be possible without these strong alliances.”

More news
The latest news from IPPro Patents
Join Our Newsletter

Sign up today and never
miss the latest news or an issue again

Subscribe now
Patent perception must shift, says Schecter
13 December 2017 | London | Reporter: Barney Dixon
Public perception must shift if the US is to find feasible solutions to patent abuse, according to chief patent counsel at IBM Manny Schecter
Patent owners winning in IPR
12 December 2017 | New York | Reporter: Barney Dixon
Patent owners are winning more than losing in IPR proceedings, according to a study from law firm Fitzpatrick, Cella, Harper & Scinto
High tech companies weigh in on Allergan deal
11 December 2017 | Washington DC | Reporter: Barney Dixon
Tech companies have argued that Allergan should not be allowed to circumvent the inter partes review process with its controversial patent deal with the Saint Regis Mohawk Tribe
BlackBerry to pay $137 million to Nokia
08 December 2017 | Waterloo | Reporter: Barney Dixon
BlackBerry will pay $137 million to Nokia after the International Chamber of Commerce’s International Court of Arbitration ruled against the company in a patent licensing dispute
ILO ruling “vote of no confidence” for Battistelli, says CSC
07 December 2017 | Munich | Reporter: Barney Dixon
In an open letter to the EPO’s heads of delegations, the CSC said that it interpreted the ILO’s decision as a “massive vote of no confidence in the president of the EPO"
China world’s top patent filer in 2016
07 December 2017 | Geneva | Reporter: Barney Dixon
China has emerged as the top patent filer in the world, accounting for nearly all of the 8 percent growth in patent applications in 2016
EPO president’s impartiality questioned at ILO
06 December 2017 | Geneva | Reporter: Barney Dixon
The International Labour Organisation has questioned the impartiality of EPO president Benoît Battistelli, in two tribunal decisions concerning an EPO employee, and found that there was a conflict of interest on the part of the president